Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 20/20 | 0.74 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.74 |
| ▸ | PTGFR | P43088 | 1/20 | 0.74 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.74 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.74 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.74 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4548362 | 0.85 | TBXA2R (1.00) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5774875 | 0.81 | TBXA2R (0.75) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL3148394 | 0.79 | TBXA2R (0.73) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5772139 | 0.79 | TBXA2R (1.00) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5777816 | 0.76 | TBXA2R (0.74) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL4548360 | 0.75 | TBXA2R (0.90) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL13317737 | 0.75 | TBXA2R (0.90) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL14621525 | 0.75 | TBXA2R (0.81) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL5777761 | 0.75 | TBXA2R (0.89) | TBXA2RPTGER1PTGFRPTGER3PTGER2 | |
| SCHEMBL13416145 | 0.74 | TBXA2R (0.90) | TBXA2RPTGDR2PTGDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110028462-A1 | Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2011-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028462-A1 | Niacin Receptor Agonists, compositions Containing Such Compounds and Methods of Treatment | LDLR, APOB, FFAR1 | TBXA2R 35/4885PTGER1 85/4885PTGFR 494/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | TBXA2R 56/4885PTGER1 171/4885PTGFR 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.